ANS-014004 is under development for the treatment of solid tumor and non small cell lung cancer (NSCLC). The therapeutic candidate is administered through oral route as tablet formulation. It acts by ...

PSP-001 is under clinical development by Prosit Sole Biotechnology (Beijing) and currently in Phase I for Norovirus Infections.

Heading into 2025, there are multiple fronts where innovative tech marvels will lead the next evolution of global living as ...

The transplant process begins with a human leukocyte antigen typing blood test to determine donor-recipient compatibility for ...

United States Trade Representative Katherine Tai announced that the United States has prevailed in its dispute under the United States-Mexico-Canada Agreement (USMCA) challenging certain Mexican biote ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

NEW YORK – Anbio Biotechnology filed this week a preliminary prospectus for an initial public offering on the Nasdaq exchange of 1.6 million shares at an anticipated offering price in the range of $5 ...

The lungs are a tempting place for cancer cells -- so much so that more than half of people with advanced cancer elsewh ...

The St. Louis-born biopharmaceutical company has a new life and new focus, four months after its board sought to dissolve the ...

Biotechnology, which uses living systems and organisms to develop new products, is transforming healthcare in incredible ways ...

The Durham company, Ummino, is targeting the sharp rise in consumer demand for fortified food and beverage products. Its ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...